Immune checkpoint analysis in ear cancer.

IF 2.4 2区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Head & Face Medicine Pub Date : 2023-11-06 DOI:10.1186/s13005-023-00395-w

M Klein, E Polgart, C Hallermann, H J Schulze, F Hölzle, K Wermker

{"title":"Immune checkpoint analysis in ear cancer.","authors":"M Klein, E Polgart, C Hallermann, H J Schulze, F Hölzle, K Wermker","doi":"10.1186/s13005-023-00395-w","DOIUrl":null,"url":null,"abstract":"Background: Among cutaneous squamous cell carcinomas, the ear (ecSCC) is one of the most common sites. Loco regional lymph node metastasis is found in six to eleven percent of cases, corresponding to increased metastasis compared to other sites. The aim of this study was to test the markers PD-L1, PD-1, CD4, CD8, and FoxP3 for suitability as prognostic predictive markers.Methods: Sixty-four patients with ecSCC were included in this study. The expression of immunohistochemical markers (PD-L1, PD-1, CD4, CD8, FOXP3) was correlated with retrospective clinic pathological parameters (lymph node metastasis, distant metastasis, lymph node metastasis during follow-up, disease progression, disease-specific death).Results: There was a correlation between increased disease specific death and a weak Foxp3 (p = 0.003) or reduced CD8 (p = 0.04). A PD-L1 expression > 1% was found in 39.1% of patients.Conclusion: The investigated markers (CD4, CD8, FoxP3, PD-1, PD-L1) seem overall rather inappropriate for prognostic evaluation in ecSCC. Only the correlation of disease specific death with CD8 or FoxP3 seems to be worth testing in larger collectives.","PeriodicalId":12994,"journal":{"name":"Head & Face Medicine","volume":"19 1","pages":"48"},"PeriodicalIF":2.4000,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626725/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head & Face Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13005-023-00395-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Among cutaneous squamous cell carcinomas, the ear (ecSCC) is one of the most common sites. Loco regional lymph node metastasis is found in six to eleven percent of cases, corresponding to increased metastasis compared to other sites. The aim of this study was to test the markers PD-L1, PD-1, CD4, CD8, and FoxP3 for suitability as prognostic predictive markers.

Methods: Sixty-four patients with ecSCC were included in this study. The expression of immunohistochemical markers (PD-L1, PD-1, CD4, CD8, FOXP3) was correlated with retrospective clinic pathological parameters (lymph node metastasis, distant metastasis, lymph node metastasis during follow-up, disease progression, disease-specific death).

Results: There was a correlation between increased disease specific death and a weak Foxp3 (p = 0.003) or reduced CD8 (p = 0.04). A PD-L1 expression > 1% was found in 39.1% of patients.

Conclusion: The investigated markers (CD4, CD8, FoxP3, PD-1, PD-L1) seem overall rather inappropriate for prognostic evaluation in ecSCC. Only the correlation of disease specific death with CD8 or FoxP3 seems to be worth testing in larger collectives.

查看原文本刊更多论文

耳癌症免疫检查点分析。

背景：在皮肤鳞状细胞癌中，耳朵（ecSCC）是最常见的部位之一。6%至11%的病例出现局部淋巴结转移，与其他部位相比，转移增加。本研究的目的是测试标志物PD-L1、PD-1、CD4、CD8和FoxP3是否适合作为预后预测标志物。方法：64例ecSCC患者纳入本研究。免疫组织化学标记物（PD-L1、PD-1、CD4、CD8、FOXP3）的表达与回顾性临床病理参数（淋巴结转移、远处转移、随访中的淋巴结转移，疾病进展、疾病特异性死亡）相关。结果：疾病特异性死亡增加与Foxp3弱表达之间存在相关性（p = 0.003）或CD8降低（p = 0.04）。PD-L1表达 > 在39.1%的患者中发现1%。结论：所研究的标志物（CD4、CD8、FoxP3、PD-1、PD-L1）似乎总体上不适合用于ecSCC的预后评估。只有疾病特异性死亡与CD8或FoxP3的相关性似乎值得在更大的集体中进行测试。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Head & Face Medicine DENTISTRY, ORAL SURGERY & MEDICINE-

CiteScore

4.70

自引率

3.30%

发文量

审稿时长

>12 weeks

期刊介绍： Head & Face Medicine is a multidisciplinary open access journal that publishes basic and clinical research concerning all aspects of cranial, facial and oral conditions. The journal covers all aspects of cranial, facial and oral diseases and their management. It has been designed as a multidisciplinary journal for clinicians and researchers involved in the diagnostic and therapeutic aspects of diseases which affect the human head and face. The journal is wide-ranging, covering the development, aetiology, epidemiology and therapy of head and face diseases to the basic science that underlies these diseases. Management of head and face diseases includes all aspects of surgical and non-surgical treatments including psychopharmacological therapies.